Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | RARB | P10826 | 3/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10609795 | 1.00 | TSHR (0.62) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL10600260 | 1.00 | TSHR (0.62) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL7766693 | 1.00 | TSHR (0.62) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL1111500 | 1.00 | TSHR (0.62) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL10606881 | 1.00 | TSHR (0.62) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL10606406 | 1.00 | TSHR (0.62) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL10608025 | 1.00 | TSHR (0.62) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL10610971 | 1.00 | TSHR (0.62) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL10708683 | 1.00 | TSHR (0.62) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL7280610 | 1.00 | TSHR (0.62) | TSHRCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322676-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARM INC (US) | 2019-10-24 | — | — | US | disclosed |
| US-20120252741-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20100105607-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2010048340-A2 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-4874894-A | Process for the production of benzenesulfonamides | HILTON DAVIS CO. (US) | 1989-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105607-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | ASNS, ALG8, ALG1 | TSHR 2513/4885CA12 993/4885CA1 2552/4885 |
| US-20120252741-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | ASNS, DNPEP, ALG8 | TSHR 2060/4885CA12 767/4885CA1 2394/4885 |
| US-20190322676-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | UGCG, MAN2B1, GBA1 | TSHR 4258/4885CA12 2763/4885CA1 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.